GlassScriptPhysician profile
Atiq Syed
NPI 1558563817
$3,559.34
in general payments reported to CMS, 2019-2025
28 companies · $996 in 2025
The $996 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $75.73 · 2021: $251 · 2022: $482 · 2023: $717 · 2024: $824 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.21 |
| Education | $184.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $481.83 | 2023-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $475.95 | 2020-2025 | Rayaldee |
| Travere Therapeutics, INC. | $328.06 | 2022-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $313.91 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $248.45 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $238.06 | 2019-2025 | Jynarque, Voyxact |
| Lilly USA, LLC | $188.66 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $161.53 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $161.47 | 2022-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $120.17 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $112.80 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $99.87 | 2021-2022 | |
| Vifor Pharma, INC. | $94.51 | 2020-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $80.65 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $66.63 | 2025 | Ozempic, Wegovy, Rybelsus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $63.56 | 2021-2023 | Benlysta |
| Renalytix Ai, INC. | $54.38 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.47 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $45.26 | 2019 | |
| Alexion Pharmaceuticals, INC. | $39.17 | 2019-2025 | Ultomiris |
| Daiichi Sankyo INC. | $21.82 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.00 | 2023 | Jynarque |
| Alnylam Pharmaceuticals INC. | $18.20 | 2024 | Amvuttra |
| Genzyme Corporation | $16.49 | 2019 | |
| Ani Pharmaceuticals, INC. | $16.30 | 2025 | Purified Cortrophin Gel |
| Cormedix INC. | $14.99 | 2024 | Defencath |
| Ardelyx, INC. | $13.51 | 2025 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atiq Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.